Tests vedolizumab in adults with ulcerative colitis or Crohn's disease
Tests vedolizumab, given by vein then under the skin, in adults with gut inflammation.
Key facts
- Who runs it
- Takeda
- Where
- Albuquerque, Atlanta, Baton Rouge, Bellevue, Birmingham, Bridgeton, Brooksville, Carmel, Cedarhurst, Chandler, Charlotte, Chevy Chase, Cincinnati, Clearwater, Colorado Springs, Columbia, Crestview Hills, Dayton, Decatur, Downers Grove, El Paso, Elmhurst, Escondido, Framingham, Fresh Meadows, Georgetown, Gilbert, Glen Burnie, Glenview, Greenville, Hialeah, Houston, Hutchinson, Kansas City, Katy, Kingsport, Kingwood, Kissimmee, Lafayette, Lake Barrington, Lake Success, Liberty Township, Little Rock, Littleton, Lubbock, Mentor, Metairie, Miami, Mobile, Murrieta, Naperville, New Bedford, New York, Newport Beach, Oak Lawn, Ogden, Orange, Orlando, Pensacola, Pinehurst, Pinellas Park, Plymouth, Portland, Providence, Reno, Roanoke, Rochester, Rockford, San Diego, Seaford, Sioux Falls, Southaven, Springboro, Springfield, Statesville, Suffolk, Summerville, Sun City, Syracuse, Tomball, Utica, Waco, Webster, Weldon Spring, West Nyack, Westfield, Westlake, Williamsburg, Wilmington, Wyoming, and Ypsilanti, United StatesSee the 101 sites
- Trial code
- Registry title
- A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 200 people, planned
- Started
- 27 Mar 2025
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Vedolizumab IV
- Vedolizumab SC
- Record updated
- 28 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with moderate to severe ulcerative colitis or Crohn's disease who did not do well on earlier treatment and will take vedolizumab.
- Age
- 18 to 80 years
- Sex
- All sexes
- Disease stage
- Moderately to severely active ulcerative colitis (complete Mayo score 6 to 12, endoscopy sub-score 2 to 3) or Crohn's disease (CDAI score 220 to 450 and SES-CD of 6 or more, or 4 or more if only the ileum is affected). Diagnosis confirmed by clinical and endoscopic evidence and a histopathology report.
- Earlier treatment
- Must have had an inadequate response, loss of response, or intolerance to at least one of: corticosteroids, immunomodulators, or advanced therapy. Cannot have had anti-integrin antibodies (such as vedolizumab or natalizumab) before, or failed more than 2 advanced treatments.
Main reasons for not taking part
- Any earlier anti-integrin antibody treatment, such as vedolizumab or natalizumab
- Active infection during screening
- Ileostomy, colostomy, severe narrowing of the intestine, or short bowel syndrome
- History of cancer, apart from a few adequately treated skin or cervical cancers
- Active brain or meningeal disease, PML, or another major nerve disorder
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- To be eligible to participate in this study, participants must meet all the following criteria:
- In the investigator's opinion, the participant can understand and comply with protocol requirements
- The participant signs and dates an electronic informed consent form (ICF) and any required privacy authorization prior to any study procedures
- The participant is 18 to 80 years of age at the time of signing the ICF
- The participant's immunization is up to date per vedolizumab US prescribing information (USPI)
- Participants must meet the contraception recommendations
- The participant has a diagnosis of moderate to severely active UC or CD defined by the following:; CD: A Crohn's Disease Activity Index (CDAI) score of 220 to 450 and a SES-CD >=6 (>=4 if isolated ileal disease) at screening OR; UC: A complete Mayo score (MS) of 6 to 12 with endoscopy sub-score of 2 to 3 at screening
- UC or CD diagnosis established prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report
- Demonstrated an inadequate response to, loss of response to, or intolerance of at least one of the following agents: corticosteroids, immunomodulators, and/or advanced therapy
Who cannot take part
- Received approved or investigational anti-integrin antibodies (i.e., vedolizumab, natalizumab, efalizumab, etrolizumab, abrilumab [AMG 181]) at any time prior to screening
- Failed (primary or secondary nonresponse) on more than 2 prior advanced treatments
- Use of corticosteroid enemas/suppositories within 2 weeks prior to screening (for UC and CD)
- Received any investigational biologic therapy <= 6 months prior to screening
- The participant has received an advanced treatment for an approved indication other than CD or UC within 60 days prior to screening; Advanced therapies include tumor necrosis factor (TNF) inhibitors, 12/23 antagonists, janus kinase (JAK) inhibitors, and sphingosine-1-phosphate (S1P) receptor modulators
- A surgical procedure requiring general anesthesia within 30 days prior to screening or planned or possible major surgery during the study period
- Participant is not on a stable dose of corticosteroid
- In the investigator's opinion, the participant meets any contraindication, warnings and precautions, drug interactions, or special population considerations per the vedolizumab USPI, or has a medical history or known allergy, hypersensitivity, or intolerance to vedolizumab or its excipients
- The participant has any evidence of an active infection during screening
- Ileostomy, colostomy, severe or symptomatic stenosis of the intestine, or short bowel syndrome
- Participants with any unstable or uncontrolled cardiovascular conditions, moderate to severe heart failure (New York Heart Association Class III or IV), pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, neurological, or other medical disorders that, in the investigator's opinion, would confound the study results or compromise participant safety
- Participants with active cerebral or meningeal disease, signs or symptoms or a history of progressive multifocal leukoencephalopathy (PML), or any other major neurological disorder, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease
- Has any of the following laboratory abnormalities during the screening period: (a) hemoglobin <8 grams per deciliter (g/dL); (b) white blood cell (WBC) count <3.0 × 10\^9 per liter (L); (c) lymphocyte count <0.5 × 10\^9/L; (d) platelet count <100 × 10\^9/L or >1200 × 10\^9/L; (e) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3.0 × the upper limit of normal (ULN); or (f) alkaline phosphatase (ALP) >1.5 × ULN. Historical laboratory data may be used for screening if available in the participant's electronic health record (EHR) within 6 weeks before screening
- History of malignancy, except for adequately treated nonmetastatic basal cell skin cancer; adequately treated squamous cell skin cancer that has not recurred for at least 1 year before screening; and adequately treated cervical carcinoma in situ that has not recurred for at least 3 years before screening. Participants with a remote history of malignancy (e.g., >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and therapy received; this must be discussed with the sponsor on a case-by-case basis before enrollment
- Participants who meet any of the following exclusion criteria will be excluded from participation in this study:
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- Presbyterian Health care servicesAlbuquerque, United StatesNo longer taking part
- AGA GA Research LLCAtlanta, United StatesContact: Justin Mendel (principal investigator)Taking people
- Digestive Healthcare of GeorgiaAtlanta, United StatesContact: Michael Galambos (principal investigator)Taking people
- Baton Rouge General Medical Center - Bluebonnet CampusBaton Rouge, United StatesContact: Jonathon Chapman (principal investigator)Taking people
- GI AllianceBellevue, United StatesContact: Nicholas Procaccini (principal investigator)Taking people
- Gastro HealthBirmingham, United StatesContact: Robert Shaffer (principal investigator)Taking people
- SSM Health Medical GroupBridgeton, United StatesContact: Yezaz Ghouri (principal investigator)Taking people
- Access Research InstituteBrooksville, United StatesContact: Salman Muddassir (principal investigator)Taking people
- Westchester Putnam Gastroenterology PCCarmel, United StatesContact: Rajiv Perinbasekar (principal investigator)Taking people
- Five Towns GastroenterologyCedarhurst, United StatesContact: Marc Fenster (principal investigator)Taking people
- AZ Gastro CareChandler, United StatesContact: Shahbaz Ali Qureshi (principal investigator)Taking people
- Charlotte Gastroenterology and Hepatology, P.L.L.CCharlotte, United StatesContact: John Gardiner Roddey (principal investigator)Taking people
- Capital Digestive CareChevy Chase, United StatesContact: Erica Cohen (principal investigator)Taking people
- Gastro Health Research - CincinnatiCincinnati, United StatesContact: Matthew Atkinson (principal investigator)Taking people
- Gastro FloridaClearwater, United StatesContact: Michael Weiss (principal investigator)Taking people
- Peak Gastroenterology AssociatesColorado Springs, United StatesContact: Bhaktasharan Patel (principal investigator)Taking people
- GI Associates Research, LLCColumbia, United StatesContact: Michael Williams (principal investigator)Taking people
- Tri-State Gastroenterology AssociatesCrestview Hills, United StatesContact: Michael Jones (principal investigator)Taking people
- DSI Research Northridge LLCDayton, United StatesContact: Rajeev Kurapati (principal investigator)Taking people
- Atlanta Center For Gastroenterology, P.C.Decatur, United StatesNo longer taking part
- Yapp, Rockford M.D. (Private Practice)Downers Grove, United StatesContact: Rockford Yapp (principal investigator)Taking people
- The Clinical Trials Network CTNX LLCEl Paso, United StatesContact: Ikenna Egbuna (principal investigator)Taking people
- IMIDeologyElmhurst, United StatesContact: Kevin Tin (principal investigator)Taking people
- Gastroenterology and Liver InstituteEscondido, United StatesContact: Naveen Gara (principal investigator)Taking people
- Gastro Health Research - FraminghamFramingham, United StatesContact: Steven Fine (principal investigator)Taking people
- Intercity GastroenterologyFresh Meadows, United StatesContact: Ghulamullah Shahzad (principal investigator)Taking people
- Amel Med LLCGeorgetown, United StatesContact: Masi Khaja (principal investigator)Taking people
- Spectrum Research Institute LLCGilbert, United StatesContact: Donna DeSantis (principal investigator)Taking people
- Woodholme GastroenterologyGlen Burnie, United StatesContact: Kenolisa Onwueme (principal investigator)Taking people
- GI Alliance GlenviewGlenview, United StatesContact: Nina Merel (principal investigator)Taking people
- Carolina Digestive DiseasesGreenville, United StatesContact: Phillip Goldstein (principal investigator)Taking people
- Doral Medical Research, LLCHialeah, United StatesNo longer taking part
- Kelsey Research FoundationHouston, United StatesContact: Sheela Chandra (principal investigator)Taking people
- MedCare Pharma LLCHouston, United StatesContact: Alan Glombicki (principal investigator)Taking people
- Spring Clinical ResearchHouston, United StatesContact: Sushma Gorrela (principal investigator)Taking people
- Integrity Advanced TherapeuticsHouston, United StatesNo longer taking part
- Hutchinson ClinicHutchinson, United StatesContact: Michael Green (principal investigator)Taking people
- Mid-America Gastro-Intestinal ConsultantsKansas City, United StatesContact: Hillary Bownik (principal investigator)Taking people
- Gastro Health & NutritionKaty, United StatesContact: Dharmendra Verma (principal investigator)Taking people
- Tri-Cities GastroenterologyKingsport, United StatesContact: Stephen Fry (principal investigator)Taking people
- One of a Kind Clinical Research Center LLCKingwood, United StatesContact: Sushovan Guha (principal investigator)Taking people
- Digestive and Liver Center of Florida, P.A.Kissimmee, United StatesContact: Basher Atiquzzaman (principal investigator)Taking people
- Combined Gastro LLCLafayette, United StatesContact: Jacque Noel (principal investigator)Taking people
- Gastroenterology and Internal Medicine Specialists, SCLake Barrington, United StatesContact: Manish Bhuva (principal investigator)Taking people
- NYU Langone Long Island Clinical Research AssociatesLake Success, United StatesNo longer taking part
- Gastro Health Research - Liberty TownshipLiberty Township, United StatesContact: Stephen Martin (principal investigator)Taking people
- UAMS Health Gastroenterology ClinicLittle Rock, United StatesNo longer taking part
- Rocky Mountain Endocopy Centers LLCLittleton, United StatesContact: Erik Springer (principal investigator)Taking people
- West Texas Research InstituteLubbock, United StatesContact: Sameer Islam (principal investigator)Taking people
- Great Lakes Gastroenterology Research, LLCMentor, United StatesContact: Keith Friedenberg (principal investigator)Taking people
- GI AllianceMetairie, United StatesContact: George Catinis (principal investigator)Taking people
- Gastro Health Research - MiamiMiami, United StatesContact: Joanna Lopez (principal investigator)Taking people
- East View Medical ResearchMobile, United StatesContact: Jonathan Siegel (principal investigator)Taking people
- United Clinical Research InstituteMurrieta, United StatesContact: John Hong (principal investigator)Taking people
- Inland Empire GastroenterologyMurrieta, United StatesNo longer taking part
- Suburban GastroenterologyNaperville, United StatesNo longer taking part
- Lucida Clinical Trials, LLCNew Bedford, United StatesContact: Jason Reich (principal investigator)Taking people
- New York Gastroenterology AssociatesNew York, United StatesContact: Ana Tuyama (principal investigator)Taking people
- Lenox Hill HospitalNew York, United StatesNo longer taking part
- Manhattan Clinical Research, LLCNew York, United StatesNo longer taking part
- Digestive Health InstituteNewport Beach, United StatesNo longer taking part
- GI Partners of Illinois - Southwest GastroenterologyOak Lawn, United StatesContact: Charles Berkelhammer (principal investigator)Taking people
- Advanced Research InstituteOgden, United StatesNo longer taking part
- Knowledge Research CenterOrange, United StatesNo longer taking part
- Endoscopic Research, IncOrlando, United StatesContact: Marlon Ilagan (principal investigator)Taking people
- Orlando Health Orlando Regional Medical CenterOrlando, United StatesContact: Udayakumar Navaneethan (principal investigator)Taking people
- Digestive and Liver Center of FloridaOrlando, United StatesNo longer taking part
- Gastro Health Research - PensacolaPensacola, United StatesContact: Frederic Newman (principal investigator)Taking people
- Pinehurst Medical Clinic IncPinehurst, United StatesNo longer taking part
- West Central Gastroenterology d/b/a Gastro FloridaPinellas Park, United StatesContact: Tejinder Glamour (principal investigator)Taking people
- MNGI Digestive Health, P.A.Plymouth, United StatesNo longer taking part
- Portland Gastroenterology CenterPortland, United StatesContact: Noemi Baffy (principal investigator)Taking people
- The Oregon Clinic, P.C.Portland, United StatesContact: Phillip Kiyasu (principal investigator)Taking people
- University GastroenterologyProvidence, United StatesContact: Lisa Mueller (principal investigator)Taking people
- Advanced Research InstituteReno, United StatesNo longer taking part
- Gastroenterology Consultants of Southwest VirginiaRoanoke, United StatesContact: Nirish Shah (principal investigator)Taking people
- Gastroenterology Group of RochesterRochester, United StatesNo longer taking part
- Rockford Gastroenterology Associates, Ltd.Rockford, United StatesContact: Sunil Patel (principal investigator)Taking people
- Medical Associates Research Group, Inc.San Diego, United StatesNo longer taking part
- ProHealth (Seaford) (Optum)Seaford, United StatesContact: Corina Serer (principal investigator)Taking people
- Sanford Center for Digestive HealthSioux Falls, United StatesContact: Ahmed Kurdi (principal investigator)Taking people
- Delta Gastroenterology and Endoscopy CenterSouthaven, United StatesContact: Ulric Duncan (principal investigator)Taking people
- DSI Research, LLCSpringboro, United StatesContact: Anjali Morey (principal investigator)Taking people
- Springfield ClinicSpringfield, United StatesContact: Dmitry Shuster (principal investigator)Taking people
- Piedmont HealthcareStatesville, United StatesContact: Brandon Marion (principal investigator)Taking people
- Centricity Research VIR - DBA IACT Health Virginia Gastroenterology Institute ResearchSuffolk, United StatesNo longer taking part
- Palmetto Primary Care Physician Division of GastroenterologySummerville, United StatesContact: Brett Van Leer-Greenberg (principal investigator)Taking people
- GI Alliance Sun CitySun City, United StatesContact: Chirag Trivedi (principal investigator)Taking people
- Syracuse VA Medical CenterSyracuse, United StatesNo longer taking part
- Texas Gastro ConsultantsTomball, United StatesNo longer taking part
- Digestive Disease MedicineUtica, United StatesContact: Harvey Allen (principal investigator)Taking people
- Digestive Research of Central Texas, LLCWaco, United StatesContact: Hanumantha Ancha (principal investigator)Taking people
- GI Alliance WebsterWebster, United StatesContact: Syed Jafri (principal investigator)Taking people
- St. Charles Clinical ResearchWeldon Spring, United StatesContact: Leonard Weinstock (principal investigator)Taking people
- Crystal Run (Optum)West Nyack, United StatesContact: Tehseen Haider (principal investigator)Taking people
- Riverview HealthWestfield, United StatesContact: Sashidhar Sagi (principal investigator)Taking people
- Northshore Gastroenterology Research, LLCWestlake, United StatesContact: Kimberly Harris (principal investigator)Taking people
- TMPG Clinical ResearchWilliamsburg, United StatesNo longer taking part
- Wilmington Gastroenterology AssociatesWilmington, United StatesContact: William King (principal investigator)Taking people
- Gastroenterology Associates of Western Michigan, P.L.C.Wyoming, United StatesContact: Allan Coates (principal investigator)Taking people
- Huron GastroYpsilanti, United StatesContact: Najm Soofi (principal investigator)Taking people
About the trial
What the trial wants to find out
Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission).
Read full original descriptionShow less
Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), participants will receive Vedolizumab as an infusion in the vein (called intravenously). After this, participants will receive Vedolizumab as an injection under the skin (called subcutaneously) for the rest of the treatment. Participants for whom the treatment does not seem to work well after 3.5 months (14 weeks) will stop treatment with Vedolizumab and can change to another treatment and also there will be additional required visits at 6 months (26 weeks) and at 1 year (52 weeks). All participants will be checked again 4.5 months (18 weeks) after their last treatment with Vedolizumab.
During the study, participants will visit their study clinic several times.
The 2 groups in the trial
- UC Participants: VedolizumabTreatment being tested
Participants with moderate to severely active UC will receive vedolizumab 300 milligrams (mg), intravenous (IV) infusion at Weeks 0 and 2. Following the first 2 vedolizumab IV doses, participant may be switched to vedolizumab 108 mg subcutaneous (SC) injection at Week 6, to be administered every 2 weeks until Week 50. Treating health care practitioner (HCP) may give an additional dose of vedolizumab IV at Week 6 with mandatory transition by Week 14.
Treatment: Vedolizumab IV and Vedolizumab SC
- CD Participants: VedolizumabTreatment being tested
Participants with moderate to severely active CD will receive vedolizumab 300 mg, IV infusion at Weeks 0 and 2. Following the first 2 vedolizumab IV doses, participant may be switched to vedolizumab 108 mg SC injection at Week 6, to be administered every 2 weeks until Week 50. Treating HCP may give an additional dose of vedolizumab IV at Week 6 with mandatory transition by Week 14.
Treatment: Vedolizumab IV and Vedolizumab SC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 4 Study Evaluating Moderate to Severely Active Ulcerative Colitis or Crohn's Disease and the Use of Vedolizumab Subcutaneous Within a Community Setting
- Plain-language title
- Tests vedolizumab in adults with ulcerative colitis or Crohn's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06581328, who can take part
- Record updated
- 28 October 2026